Personalized Cancer Vaccine Therapeutics is an outcome of the Breast Cancer Startup Challenge organized by the Center for Advancing Innovation, Avon Foundation and National Cancer Institute. The mission of PCV Therapeutics is to create cost-effective personalized cancer vaccines, specific for each patient, to treat the cancer and prevent future recurrence. We are a team of enthusiastic and dedicated scientists who are passionate about this cause.
Harnessing the immune system to outsmart cancers:
The human immune system is highly efficient in detecting and eliminating pathogens. At PCV Therapeutics, we harness this adaptation to develop vaccines capable of detecting and eliminating cancers by training the patient’s immune system to recognize the cancer as a foreign pathogen, rather than a cancer. Our lead vaccine candidate has the potential to actively eradicate the cancer (therapeutic) and also prevent future recurrence and metastasis (prophylactic).
Because all cancers evolve differently, we personalize our vaccines to specifically target the tumor cells unique to each patient. This personalized approach equips our vaccine with the versatility necessary to combat any cancer type. This is especially valuable for cancers lacking drugable targets, such as Triple Negative Breast Cancer, which is very aggressive and is currently associated with very poor prognosis.
Progress Report:
PCV Therapeutics is going through an exciting phase of growth. We are in the process of incorporating our company in the state of Missouri. Our business plan is undergoing careful refinement to enable our license application submission to the Office of Technology Transfer at NCI and also to apply for seed funding. We are collaborating with Dr. Dennis Klinman, the inventor of our technology, and other KOL’s to integrate their expertise with our ideas in order to successfully advance this technology. We have arranged meetings with potential seed investors and are in the process of recruiting an experienced management team as well.
Harnessing the immune system to outsmart cancers:
The human immune system is highly efficient in detecting and eliminating pathogens. At PCV Therapeutics, we harness this adaptation to develop vaccines capable of detecting and eliminating cancers by training the patient’s immune system to recognize the cancer as a foreign pathogen, rather than a cancer. Our lead vaccine candidate has the potential to actively eradicate the cancer (therapeutic) and also prevent future recurrence and metastasis (prophylactic).
Because all cancers evolve differently, we personalize our vaccines to specifically target the tumor cells unique to each patient. This personalized approach equips our vaccine with the versatility necessary to combat any cancer type. This is especially valuable for cancers lacking drugable targets, such as Triple Negative Breast Cancer, which is very aggressive and is currently associated with very poor prognosis.
Progress Report:
PCV Therapeutics is going through an exciting phase of growth. We are in the process of incorporating our company in the state of Missouri. Our business plan is undergoing careful refinement to enable our license application submission to the Office of Technology Transfer at NCI and also to apply for seed funding. We are collaborating with Dr. Dennis Klinman, the inventor of our technology, and other KOL’s to integrate their expertise with our ideas in order to successfully advance this technology. We have arranged meetings with potential seed investors and are in the process of recruiting an experienced management team as well.
RSS Feed